Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2007369 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3925251 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3927723 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL2007366 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3925245 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL7069618 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3928640 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL3928631 | 1.00 | TLR4 (0.93) | TLR4LY96 | |
| SCHEMBL6062580 | 0.96 | TLR4 (1.00) | TLR4LY96 | |
| SCHEMBL14376659 | 0.96 | TLR4 (1.00) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7541020-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2009-06-02 | — | — | US | disclosed |
| US-7063967-B2 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2006-06-20 | — | — | US | disclosed |
| US-20040063647-A1 | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| US-6649172-B2 | 5-(p-carboxybenzyloxy)-2-oxybenzaldehyde derivatives; vaccine adjuvants | CORIXA CORPORATION | 2003-11-18 | — | — | US | disclosed |
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION (US) | 2003-10-23 | — | — | US | disclosed |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | CORIXA CORPORATION | 2003-05-15 | — | — | US | disclosed |
| WO-2003037275-A2 | COMPOSITIONS AND METHODS FOR VIRAL DELIVERY | CORIXA CORPORATION (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1265840-A2 | NOVEL AMPHIPATHIC ALDEHYDES AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2002-12-18 | — | — | EP | disclosed |
| US-20010053363-A1 | Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors | CORIXA CORPORATION | 2001-12-20 | — | — | US | disclosed |
| WO-2001070663-A2 | NOVEL AMPHIPATHIC ALDEHYDES AND THEIR USE AS ADJUVANTS AND IMMUNOEFFECTORS | CORIXA CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199460-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 70/4885LY96 87/4885 |
| US-20030092643-A1 | Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors | DNPEP, CD68, MGAT3 | TLR4 70/4885LY96 87/4885 |
| US-20040063647-A1 | Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors | MAVS, TLR3, LY96 | TLR4 8/4885LY96 3/4885 |
| US-20010053363-A1 | Novel amphipathic aldehydes and their uses as adjuvants and immunoeffectors | MAVS, TLR3, LY96 | TLR4 7/4885LY96 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.